Advanced Androgen Blockage in Nonmetastatic Castration-Resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide – Beyond the Abstract
quantitative estimates of comparative treatment effects for nmCRPC agents, apalutamide, enzalutamide, darolutamide, network meta-analysis of agents receiving FDA approval for nmCRPC, prostate-specific antigen progression-free survival.